Novo Nordisk Says Wegovy Pill Delivered Substantial Weight Loss, Mobility Improvement in Phase 3 Trial Analyses
MT Newswires Live
May 13
Novo Nordisk (NVO) presented new analyses from its phase 3 OASIS 4 trial showing that adults treated with Wegovy pill achieved substantial weight loss and improved physical function, the drugmaker said Wednesday.
Nearly 29% of adults taking oral semaglutide 25 mg were early responders, achieving average weight loss of 13.2% at 16 weeks and 21.6% by week 64, while non-early responders still recorded an average weight loss of 11.5% by the end of the trial, the company said.
A separate analysis showed that more than 77% of participants with poor physical function achieved clinically meaningful improvements in mobility and daily activities, compared with 42.9% in the placebo group, the company added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.